HIGHLIGHTS
- who: Yuwen Bao and colleagues from the School of Health Policy and Management, Nanjing Medical University, Nanjing, China have published the research work: Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage, in the Journal: (JOURNAL)
- what: The aims of the study were as follows: to estimate the cost-effectiveness of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with previously treated HER2-positive metastatic BC from the perspective of the Chinese healthcare system; and_ . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.